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Abstract
Osteoporosis is a disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue, leading to enhanced bone fragility and susceptibility 
to fractures. Osteoporosis also results in loss of bone mineral density throughout 
the body, including the maxilla and mandible. Successful osseointegration of dental 
implants is attributed to their ability to integrate well with bone. The influence 
of bone quality on dental implant osseointegration has been discussed in several 
studies, and higher rates of dental implant failure have been reported in patients 
with low bone quality and an inadequate bone volume. Osteoporosis represents 
a risk factor for osseointegration, and this relationship may be derived from the 
association of the disease with a deficiency in bone formation. This condition would 
compromise the healing capacity and the apposition of bone at the implant inter-
face. Currently, there is no clear consensus regarding dental implant treatment in 
osteoporotic individuals. Studies have revealed contradictory reports regarding the 
success and failure of dental implants in patients with osteoporosis. Antiresorptive 
agents have been widely used to treat osteoporosis. Dental implant placement in 
patients on bisphosphonate therapy may trigger osteonecrosis of the bone. Hence, 
it is important to analyze factors that have to be taken into consideration prior to 
implant therapy in patients with osteoporosis and those undergoing treatment. This 
chapter outlines dental implant osseointegration under osteoporotic conditions. 
The possible effect of bisphosphonate therapy on dental implant survival will also 
be discussed based on the current literature.
Keywords: osteoporosis, osteopenia, bisphosphonates, osseointegration, implant, 
bone mineral density, risk factors
1. Introduction
Osteoporosis is a systemic skeletal disease that deteriorates bone mass and 
strength and affects the microarchitecture of bone, thus increasing bone turnover 
and bone fragility [1]. Osteoporosis is categorized into primary and secondary 
types. Primary osteoporosis is considered decreased bone density attributed 
to aging, postmenopausal conditions and idiopathic osteoporosis. Secondary 
osteoporosis occurs in patients with predisposing factors, such as other endocri-
nopathies and a history of using some drugs. Osteoporotic bone is characterized 
by a decreased thickness, deranged trabecular structure, reduced mineral content, 
as well as an increased carbonate-to-phosphate ratio [2]. The reduction in osteoid 
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formation is attributed to the absence of or a deficit in pre-osteoblast differentiation 
into osteoblasts or a reduction in the number of osteoprogenitor cells and defects in 
their proliferation and differentiation [3].
Dental implant placement has become a common and frequent option for tooth 
replacement. The success of dental implants largely depends on their osseointegra-
tion. Factors that interfere with osseointegration act as potential threats to implant 
survival. Osteoporosis is considered a questionable condition in dental implant 
placement since it affects the jaw bones, and bisphosphonates (BPs) are the first 
line of therapy [4–6]. Local and systemic factors can influence the osseointegration. 
The implant surface and the bone are the main interacting entities, and changes to 
these affect the healing and osseointegration of the implant. It is recognized that 
any compromise in the bone quality and quantity adversely affects the osseoin-
tegration. A microrough implant surface results in better osseointegration than a 
smooth implant surface. The relationship between osteoporosis and bone forma-
tion around implants is still unclear [7, 8]. Osteoporosis in the elderly, especially in 
postmenopausal women, is significantly correlated with tooth loss [9]. In fractures, 
delayed bone healing occurs due to low bone density, poor bone quality and osseous 
microstructural changes [10]. The endosseous implant healing mechanism is similar 
to that of bone fracture healing; hence, it is reasonable to assume that dental implant 
survival may be negatively affected by osteoporosis [11]. Animal studies have shown 
a relatively low rate of osseointegration in an osteoporotic environment [12, 13]. 
While most of these experimental studies were carried out on long bones rather 
than jaw bones, [14] studies of experimentally induced osteoporosis in the mandible 
failed to show a significant difference in peri-implant bone formation [15–18].
2. Pathophysiology of osteoporosis
Osteoporosis is a condition characterized by decreased bone mineral density 
and deteriorated bone microarchitecture and hence compromised bone quality. 
Osteoporosis can be classified into primary and secondary types. Primary osteo-
porosis can also be subclassified as type I and type II osteoporosis [17]. Type I 
osteoporosis occurs primarily due to the loss of trabecular bone, leading to distal 
forearm and vertebral body fractures. Type II osteoporosis is also known as senile 
osteoporosis and mainly occurs in men and women over the age of 70 years due to 
the loss of cortical and trabecular bone. Osteoporosis may also result from genetic 
and endocrine disorders, hypogonadal states, deficiencies, drug-induced and 
inflammatory states, and hematologic and neoplastic disorders as secondary causes. 
Estrogen deficiency is thought to be critical in the pathogenesis of postmenopausal 
osteoporosis. In the postmenopausal period, the bone structure changes due to 
estrogen deficiency, and osteoporosis can occur as a result of an imbalance in bone 
remodeling leading to enhanced bone resorption [3].
Osteoporosis leads to bone demineralization, which begins to manifest clini-
cally in the fourth and fifth decades of life. Modifiable and nonmodifiable risk 
factors are responsible for osteoporosis [19]. Nonmodifiable risk factors include 
age, sex, genetic factors and early menopause, while modifiable risk factors include 
inadequate calcium consumption, lack of exercise, and behavioral factors, such 
as smoking and alcoholism. Other factors that can contribute to the development 
of osteoporosis include certain endocrine diseases, such as hyperparathyroidism, 
chronic renal and hepatic disease, malabsorption, and the use of certain drugs, such 
as oral glucocorticoids [18, 19].
The role of estrogen in the development of osteoporosis is well documented. 
Studies have shown that sex steroids, particularly estrogen, are important in 
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developing peak bone mass and that estrogen deficiency is an important deter-
minant of bone loss in both sexes [20, 21]. Estrogen can directly and/or indirectly 
affect osteoclasts, osteoblasts and osteocytes. It has been firmly established that 
these cells express functional estrogen receptors, [22] and studies have clearly 
demonstrated that estrogen can induce osteoclast apoptosis through the osteoclast-
specific deletion of estrogen receptors. This can reduce osteoclast apoptosis and 
increase the osteoclast lifespan, which results in decreased trabecular bone mass 
(Figure 1) [23, 24]. Aging and estrogen deficiency may lead to an impairment in 
bone formation involving oxidative stress. Estrogen deficiency can also lead to a 
marked increase in NF-kB activity in osteoblasts. In osteoporotic patients, estrogen 
treatment induces the expression of sclerostin, a potent inhibitor of bone forma-
tion [25]. As sclerostin is expressed by osteocytes, estrogen also affects osteocytes. 
Estrogen deficiency may enhance the rate of bone loss by stimulating the synthesis 
of several inflammatory cytokines that regulate osteoclast generation, such as IL-1, 
IL-2, IL-6, and prostaglandin E [26].
A recent study among Swedish women showed a previous history of fracture 
and low bone mineral density as important factors that can lead to an increased 
rate of hip and fragility fractures among them [27]. Another study conducted in 
the United States revealed that several factors, such as age, self-reported health, 
weight, height, self-reported physical activity, history of fracture after the age of 
50, parental hip fracture, smoking, use of corticosteroids, and treated diabetes, may 
be early indicators of hip fractures [28]. Factors associated with an increased risk 
for osteoporosis in men include glucocorticoid treatment, hypogonadism, excessive 
alcohol consumption, anticonvulsant use, osteomalacia, severe hyperthyroidism, 
and bone marrow neoplasia [29].
3. Dental implants and osteoporosis
Osteoporosis causes a range of skeletal changes that may impact the feasibility 
of dental implant placement. Greater alveolar ridge resorption, altered trabecular 
patterns in the anterior maxilla and posterior mandible, erosion of the inferior 
border of the mandible and increased resorption and thinning of the inferior 
mandibular cortical margin have been reported among osteoporotic individuals 
[30, 31]. Subjects with osteoporosis show a decreased number and thickness of 
trabecular plates as a characteristic feature of the disease. There have also been 
anecdotal reports that the incidence of maxillofacial fractures during the placement 
of endosseous implants is increased in patients with osteoporosis [32]. Additionally, 
Figure 1. 
Orthopantomogram of a 65-year-old patient with osteoporosis. Note the area of low bone density, alveolar bone 
loss and tooth loss.
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bone changes evident on panoramic radiographs can be correlated with general 
osteoporosis, and dental radiography can serve as both a reliable indicator of bone 
loss in osteoporosis and a useful tool for diagnosing skeletal osteoporosis [33].
The osseointegration of an implant is a wound healing process that depends 
upon the quality, quantity, and healing capacity of the host bone and various other 
systemic conditions. Osseointegration is based on intimate bone-implant contact 
achieved during healing. Thus, any condition affecting bone quality or quantity or 
microarchitectural changes in bone structure, including a reduction in the cancel-
lous bone volume and bone-implant contact, could theoretically have a negative 
impact on the survival and function of an endosseous implant [34]. There are 
relatively few absolute contraindications to rehabilitation with dental implants, 
including a recent myocardial infarction or cerebrovascular accident, history of 
valvular prosthesis placement, immune suppression, bleeding issues, active treat-
ment of malignancy, drug abuse, psychiatric illness, and intravenous BP treatment 
[35]. Some relative contraindications and conditions that may unfavorably impact 
the outcomes of dental implant placement discussed in the literature include 
adolescence, aging, osteoporosis, smoking, diabetes, positive IL-1 genotype, human 
immunodeficiency virus infection, cardiovascular disease and hypothyroidism 
[36–38]. Controversy about the importance and effects of osteoporosis in dental 
therapy has continued [39].
In a study of implant placement in patients diagnosed with osteoporosis, Friberg 
et al. [40] found a success rate of 97% for the maxilla and 97.3% for the mandible on 
follow-up. Most studies have shown that it is feasible to place implants in subjects 
with osteoporosis, with success rates similar to those in healthy subjects, even in 
cases of poor bone quality during or after placement [4, 41–44].
4. Osteoporosis in implant Osseointegration
The osseointegration of an implant can be affected by the characteristics of the 
implant, the surgical procedure, and patient-dependent variables that can affect 
the quantity and quality of bone (Table 1). Osteoporosis, characterized by bone 
loss, microstructural alterations and a reduced bone regeneration capacity, has been 
considered a potential contraindication to or risk factor for dental implant place-
ment. It has been established that osteoporosis affects the jaw in the same manner as 
other bones of the skeleton and thus may also alter the metabolic microenvironment 
of bone around the implant [56]. Bone is constantly metabolized throughout life by 
bone-resorbing osteoclasts and bone-forming osteoblasts. Osteocytes play an active 
role in modulating the process of bone metabolism through the lacunocanalicular 
system [57, 58]. Studies in osteoporotic animal models have shown altered osseoin-
tegration, especially in trabecular bone, which resulted in a significant reduction in 
bone-implant contact [59–61].
Elucidation of the role of osteocytes in peri-implant bone remodeling will 
help clarify the dynamics of bone metabolism following osseointegration. Since 
osteocytes are the terminal cells of osteoblasts, understanding the relationship 
between osteocytes and implants will also shed light on the relationship between 
osteoblasts and implants in early bone formation. Research on the influence of 
estrogen deficiency and its treatment with alendronate and estrogen on bone den-
sity around osseointegrated implants in rats has shown that estrogen deprivation 
has a negative effect only on trabecular bone and that treatment with estrogen and 
alendronate can effectively prevent bone loss around osseointegrated implants [62]. 
Histological studies in humans have also shown the osseointegration of implants 
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retrieved from osteoporotic individuals [63, 64]. A histological study that evaluated 
the bone-implant contact of failed implants after retrieval showed no differences 
between implants originating from patients with and without osteoporosis [41]. 
The most important complication of implant placement in osteoporotic patients 
is bisphosphonate-related osteonecrosis of the jaw (BRONJ), that interferes with 
osseointegration. BPs act by inhibiting and inducing the apoptosis of osteoclasts, 
increasing collagen synthesis and inhibiting osteoblast proliferation. A systematic 
review showed that the placement of dental implants in osteoporotic patients who 
used oral BPs for less than five years did not develop BRONJ and that most adverse 
effects were related to the intravenous administration of BPs [65].






49 cases, 49 controls,
5 osteoporosis, 7 osteoporosis
3.9 years No association between dual-
energy X-ray absorptiometry 
values or diagnosis of 




13 cases of osteoporosis
3.4 years Successful implantation in 
osteoporosis provided adapted 
bone technique used and 




Retrospective cohort, 7 cases 
of osteoporosis, 11 controls
5 years Mandibular osteoporosis a risk 




19 cases of osteoporosis, 20 
controls
9 months No difference in implant survival 
between the two groups
Amorim et al. 
(2007) [47]
Prospective, 19 cases of 
osteoporosis, 20 controls




Retrospective study,187 total, 
29 cases of osteoporosis




Retrospective, 19 cases of 
osteoporosis, 393 controls
2 years Failure in 9 (13.24%) cases of 




Retrospective,94 controls, 57 
cases of osteopenia, 41 cases 
of osteoporosis
10 years No difference between controls 




Cross-sectional,46 cases of 
osteoporosis, 16 cases of 
osteopenia, 115 controls
6 ± 4 years Failure in 6 (13%) cases of 
osteoporosis, 3 (18.75%) cases 
of osteopenia, and 15 (13%) 
controls
de Souza et al. 
(2013) [52]
Retrospective, 6 cases of 
osteoporosis, 186 controls
1 year Failure in 12 (50%) cases of 
osteoporosis and 203 (29%) 
controls
Famili and Zavoral 
(2015) [53]
Case–control study, 30 
patients
2 years No difference: 100% survival
Siebert et al. 
(2015) [54]
Prospective study, 24 
patients
1 year 100% implant survival
Temmerman et al. 
(2017) [55]
Prospective study, 48 
patients
1 year 100% implant survival
Table 1. 
Studies evaluating the outcome of dental implants among subjects with osteoporosis.
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5. Dental implants and bisphosphonate therapy
Bisphosphonates are widely prescribed for the management of osteoporosis. 
They are pyrophosphate analogs containing a phosphate-carbon-phosphate bond, 
which is stable against chemical and enzymatic hydrolysis. BPs strongly bind to 
hydroxyapatite (HA) crystals and potently inhibit osteoclast-mediated bone resorp-
tion while minimally inhibiting osteoblast activity [66]. BPs are used for increasing 
or maintaining bone mass and reducing excessive bone turnover [67]. By inhibiting 
osteoclast-mediated bone resorption, BPs contribute to an increase in bone mineral 
density as well as a decrease in the risk of fracture [68, 69]. Two routes of admin-
istration are commonly used: oral and intravenous. BPs act almost exclusively on 
bone when administered at physiological doses because of their specific affinity to 
bone; they are deposited both in newly formed bone and in proximity to osteoclasts. 
The half-life of BPs in the circulation is quite short, ranging from thirty minutes to 
two hours [70]. However, once incorporated into bone tissue, they can persist for up 
to 10 years, depending on the skeletal turnover time [71]. Oral BPs are commonly 
used in the treatment of osteoporosis, Paget’s disease, and osteogenesis imperfecta, 
whereas intravenous BPs are used in the treatment of osteolytic tumors, hyper-
calcemia of malignancy, multiple myeloma, bone metastases from solid tumors, 
and other tumors [72, 73]. The most common oral BPs are alendronate (Fosamax), 
risedronate (Actonel), and ibandronate (Boniva).
There have been conflicting reports regarding installation of dental implants 
in patients undergoing bisphosphonate therapy [74, 75]. Experimental studies 
have shown a positive effect of BPs on peri-implant bone in experimental animals 
[76, 77]. Although some studies have reported that BPs have no effect on implant 
stability, [78] a few other reports have suggested that BPs may have a negative 
impact on osseointegration. Additionally, osteointegration failure has been reported 
in patients on BP therapy [79–81]. Current guidelines indicate that implant place-
ment may be avoided if the patient has a serious bone disease or is on high doses of 
BPs. Osteoporotic patients on lower doses need to provide fully informed consent 
before proceeding with treatment, and patients with existing implants on BP 
therapy should be regularly monitored. Increased bone density around the implant 
may also occur. If bone pain or loss of integrity occurs, the superstructure should be 
removed, and the implant should be left submerged [82]. In such cases, bone sur-
gery must be avoided because the bone is exceedingly dense, and avascular necrosis 
may occur (Figure 2).
The chances of developing osteonecrosis depend on the potency and duration of 
BP exposure [84–86]. BRONJ is a condition characterized by nonhealing exposed 
necrotic bone in the mandible or maxilla persisting for more than 8 weeks in a patient 
who has taken or is currently taking a BP and who has no history of radiation therapy 
of the jaw [84, 87]. Incidents of osteonecrosis of the jaw have been reported in 
persons using BPs and undergoing invasive dental treatment procedures, including 
tooth extraction, dental implant placement, and surgical and nonsurgical periodon-
tal treatment [88, 89]. Although BPs have been reported to cause oral mucosal altera-
tions, the changes occurring in the jaw bone are of greater significance to the dentist 
[90, 91]. Osteonecrosis of the jaw is less often reported among patients who have 
received treatment with oral BPs at lower doses, used for osteoporosis, than among 
patients who have received treatment with higher doses, used for metastatic cancer. 
Even though the exact incidence of BRONJ is unknown, reports have estimated it to 
be approximately 1 in 10,000 for intravenous BPs. There is also an incomplete under-
standing of how BP therapy may affect tissue healing and the success rate of dental 
implantation [75, 80]. Advanced cases of BRONJ can lead to pathological fractures, 
especially in edentulous patients with long-standing oral implants [92].
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6. Bisphosphonate-related osteonecrosis of the jaw
BPs alter the bone tissue metabolism by inhibiting bone resorption and reducing 
bone turnover. At the cellular level, BPs affect the recruitment of osteoclasts, their 
viability, the bioavailability of their progenitors, and their effect on bone. From a 
molecular point BPs have been proposed to modulate the function of osteoclasts 
by reacting with a surface receptor or with an intracellular enzyme [93]. BRONJ is 
defined as an area of exposed bone in the maxillofacial region that does not heal 
within 8 weeks in a patient who is receiving treatment with a BP. BRONJ develops 
secondary to the mechanisms of action of BPs in anti-osteoclastic and antiangio-
genic activities, which alter bone metabolism, inhibit bone resorption and reduce 
bone turnover. Additional signs and symptoms may include pain, swelling, pares-
thesia, suppuration, soft tissue ulceration, intra- or extraoral sinus tract formation, 
tooth loosening, and radiographic variability. These symptoms most commonly 
occur at sites of previous tooth extractions or other dental surgical interventions 
but may occur spontaneously. The exact role of BPs remains to be determined, and 
alterations in bone homeostasis coupled with odontogenic or surgical insult, or 
both, may be key to the development of osteonecrosis of the jaw [88, 93]. Cases of 
BRONJ are more common when frequent doses of intravenous BPs are used in treat-
ing malignancy than when oral BP regimens are used in treating osteoporosis [94].
The diagnosis of BRONJ is primarily based on the patient’s history and the find-
ings of a clinical examination. Most of the time, these patients have necrotic bone 
exposure ranging from a few millimeters to larger areas and can be asymptomatic for 
weeks, months, or years (Figure 3). The incidence of BRONJ is higher in the mandi-
ble than in the maxilla and in areas of thin mucosa overlying bony prominences, such 
as tori and the mylohyoid ridge. The management of BRONJ mainly comprises pain 
control measures, antibiotic therapy, mouth rinsing, BP discontinuation, hyperbaric 
chamber therapy, laser therapy, and surgical debridement [95, 96]. Assessments 
Figure 2. 
Schematic diagram showing the possible mechanism of development of BP-associated osteonecrosis. BP, 
bisphosphonate (adapted and modified from Anil et al. [83]).
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of markers of bone resorption, such as the serum C-terminal telopeptide of type 
I collagen; CTx or ITCP) test, can be used to assess the risk of developing BRONJ. 
Patients with a CTx level lower than 150 pg./mL should consider discontinuation of 
BP therapy for a period of 4–6 months.
7. Conclusion
Osteoporosis is a common skeletal disorder characterized by reduced bone mass 
and altered bone architecture, leading to an increase in bone fragility and the risk 
of fracture. This condition is associated with a decrease in bone quality and quan-
tity, which might affect dental implant osseointegration. The placement of dental 
implants in patients with osteoporosis is still debated because of the quality of the 
bone, which is a key factor that determines the success of dental implantation. 
Although osteoporosis is not considered a risk factor for dental implant failure, 
the initial implant stability can be influenced by both the local and skeletal bone 
density, and the healing time is prolonged in osteoporotic patients. While the risk 
of osteonecrosis of the jaw in patients on BPs is low, patients should be informed of 
this risk and sign a consent form including this specific point. Based on the available 
literature, it can be concluded that implants placed in patients with systemic osteo-
porosis did not present higher failure rates than those placed in patients without 
osteoporosis.
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Figure 3. 
BRONJ in a 63-year-old woman subsequent to extraction of mandibular molar. The patient was on 
intravenous zoledronate for 1 year (adapted and modified from Anil et al. [83]).
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